Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's disease: Strategies and research directions. — Anti-amyloid monoclonal antibodies (MABs) have introduced a new era of Alzheimer's disease (AD) therapeutics with disease-targeted drugs. Three agents ---...

Evidence span

Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's disease: Strategies and research directions. — Anti-amyloid monoclonal antibodies (MABs) have introduced a new era of Alzheimer's disease (AD) therapeutics with disease-targeted drugs. Three agents ---...

From Cummings JL 2025, Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Method & conditions

Evidence type

experimental

Method

manual state transition; control details require source inspection

Species

Homo sapiens

Conditions

Animals; Humans; Alzheimer Disease; Antibodies, Monoclonal; Amyloid beta-Peptides — Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2025

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required